Global Ascites Market

Global Ascites Market Size Insights Forecasts to 2035

• The Global Ascites Market Size Was Estimated at USD 2.45 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.58 % from 2025 to 2035
• The Worldwide Ascites Market Size is Expected to Reach USD 4.01 Billion by 2035
• North America is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Ascites Market Size Was Worth Around USD 2.45 Billion In 2024 And Is Predicted To Grow To Around USD 4.01 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 4.58 % From 2025 To 2035. The ascites market is influenced by the growing rates of liver-related diseases, which are creating a demand for effective ascites treatment solutions. The growing prevalence of liver-related diseases is forcing the healthcare sector to address the complications arising from these diseases, including ascites.

 

Market Overview

Ascites is an abdominal swelling due to an abnormal accumulation of fluid in the peritoneal cavity. The disease makes the patient unable to move around freely, and the patient becomes more susceptible to various abdominal infections. In addition, the fluid may accumulate in the chest and encase the lungs in extreme cases. The common signs and symptoms associated with the disorder include increased abdominal size, increased body weight, shortness of breath, feeling full or heavy, bloating, indigestion, vomiting, increased swelling in the lower limbs, haemorrhoids, etc. In addition, the patients suffering from the disorder may also experience difficulty in sitting, tiredness, and constipation. These techniques include ultrasound and computerised tomography scans. In addition, the doctor may use paracentesis, whereby a needle or catheter is inserted into the peritoneal cavity to determine the cause of the disease.

 

Report Coverage

This research report categorizes the ascites market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the ascites market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the ascites market.   

   

Driving Factors  

The growing instances of liver cirrhosis, which result in a reduction of the functioning of the liver, are the key factors responsible for the growth of the market. Apart from this, the growing instances of various related factors, such as excessive alcohol intake, fatty liver disease, various infections, severe malnutrition, lymphatic disorders, etc., are also contributing to the growth of the market. In addition to this, the high usage of diuretics, such as furosemide or spironolactone, for the treatment of the condition is acting as another significant growth-inducing factor for the market, the high investment of various market players in R&D activities for the development of new treatment options, which can help in the alleviation of the condition with minimum side effects, is further contributing to the growth of the market. Moreover, the growing demand for automated low-flow pumps due to the various benefits associated with them, such as the alleviation of the condition with minimum side effects, gradual removal of the fluid from the body, etc., is likely to boost the growth of the market.

 

BD (Becton, Dickinson and Company) announced that the U.S. FDA granted expanded 510(k) clearance for its PeritX Peritoneal Catheter System, making it the first and only at-home system indicated for both malignant and non-malignant ascites drainage in the United States.

 

Restraining Factors  

The high R&D costs of developing drugs for treating diseases, along with the limited access to advanced treatments in underdeveloped regions of the world, act as major restraints to the growth of the global ascites market.

 

Market Segmentation    

The ascites market share is classified into type, diagnosis, and end user.    

 

• The transudative ascites segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.        

Based on the type, the ascites market is divided into transudative ascites and exudative ascites. Among these, the transudative ascites segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. This industry segment continues to dominate since it is more prevalent, and healthcare professionals have a solid understanding of its pathophysiology. Diuretics and lifestyle changes are possible treatment strategies that concentrate on controlling the underlying causes.

 

A cirrhotic patient treated with empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had refractory ascites and pleural effusion that completely resolved, according to a recent case report published by the Journal of Clinical and Translational Hepatology.

 

• The ultrasound segment accounted for the largest market share in 2024 and is anticipated to grow at a notable CAGR over the forecast period.       

Based on the diagnosis, the ascites market is segmented into ultrasound, CT scan, laparoscopy and angiography. Among these, the ultrasound segment accounted for the largest market share in 2024 and is anticipated to grow at a notable CAGR over the forecast period. This is because of its broad applicability, non-invasive nature, and ability to produce rapid, efficient outcomes that are consistent with modern medical procedures. Its affordability and capacity to detect fluid presence without requiring a great deal of patient preparation further contribute to its popularity.

 

A recent study explored the use of deep learning for ultrasound-based auxiliary diagnosis of emergency ascites, aiming to improve rapid detection in critical care settings.

 

• The hospitals & clinics segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.      

Based on the end user, the ascites market is divided into hospitals & clinics, ambulatory surgical center and diagnostic centers. Among these, the hospitals & clinics segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Hospitals dominate the ascites market due to their extensive treatment programs and array of services that serve a wider patient base. Many patients choose them because of their state-of-the-art facilities, which offer comprehensive diagnostic and treatment options for managing ascites.

Regional Segment Analysis of the Ascites Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the ascites market over the predicted timeframe.     

Asia Pacific is anticipated to hold the largest share of the ascites market over the predicted timeframe. The market for ascites in the Asia-Pacific region is influenced by various factors, which are all related to each other. For instance, the growing prevalence of liver cirrhosis, cancer, and chronic infections is raising the patient pool for the treatment of ascites.

The study found that the most frequent causes of ascites were liver cirrhosis (27.9%) and cancer (28.9%). The majority of ascites' malignant causes were gastrointestinal (colon, liver, pancreas, and bile duct) and female (breast and ovarian) cancers. Ascites linked with liver cirrhosis was primarily caused by hepatitis B infection (20.5%) and metabolic-associated fatty liver disease (MASLD, 35.5%). All causes of ascites were linked to an older age (> 40 years).

 

Increasing awareness about the minimally invasive procedures, including paracentesis and indwelling catheter systems, is also positively influencing the market. The growing medical infrastructure in the Asia-Pacific region, including countries such as India, China, and Japan, along with the government initiatives, is also contributing to the growth of the market. Increasing demand for home care is also positively influencing the market.

 

North America is expected to grow at a rapid CAGR in the ascites market during the forecast period. The North American ascites market is driven by factors such as advanced healthcare facilities, high incidence of liver cirrhosis and cancer-related ascites, and high adoption of minimally invasive procedures such as paracentesis and indwelling catheter systems. Strategic initiatives in the identification of biomarkers and advanced imaging techniques are increasing diagnostic accuracy, and the integration of digital health is also benefiting patients. Increasing emphasis is also being placed on reducing hospitalisations and improving quality of life, which is creating opportunities for innovative therapies.

 

The U.S. FDA approved Sequana Medical’s Alfapump system for the treatment of recurrent or refractory ascites due to liver cirrhosis. This marks a major milestone in managing one of the most debilitating complications of advanced liver disease.

 

Competitive Analysis:   

The report offers the appropriate analysis of the key organizations/companies involved within the ascites market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.  

 

List of Key Companies

• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• GSK plc
• Johnson & Johnson Private Limited
• Lilly
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• WOCKHARDT
• Others  

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

 

Recent Development

 

• In December 2025, Pharmanovia announced the launch of Korjuny (Catumaxomab) in Germany, marking a significant milestone in oncology care. Catumaxomab is the first and only approved drug therapy for malignant ascites, a rare and debilitating complication of advanced-stage cancer.

 

Market Segment  

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the ascites market based on the below-mentioned segments: 

  

Global Ascites Market, By Type

• Transudative Ascites
• Exudate Ascites

 

Global Ascites Market, By Diagnosis

• Ultrasound
• CT Scan
• Laparoscopy
• Angiography

 

Global Ascites Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centre
• Diagnostic Centres

 

Global Ascites Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the market size and growth rate?

The market was USD 2.45 billion in 2024 and is expected to reach USD 4.01 billion by 2035, growing at a CAGR of 4.58% from 2025 to 2035.

 

2. What is ascites, and what are its symptoms?

Ascites is abnormal fluid buildup in the peritoneal cavity, causing abdominal swelling. Symptoms include increased abdominal size/weight, shortness of breath, bloating, indigestion, leg swelling, fatigue, and constipation.

 

3. Which type of ascites leads the market?

Transudative ascites held the largest share in 2024 and is projected to grow at a significant CAGR, driven by higher prevalence linked to liver cirrhosis and established treatments like diuretics.

 

4. What diagnosis method dominates?

Ultrasound accounted for the largest market share in 2024 and is expected to grow at a notable CAGR due to its non-invasive, affordable, and rapid detection of fluid.

 

5. Which end-user segment has the highest revenue?

Hospitals & clinics led revenue in 2024 and are anticipated to grow at a significant CAGR, offering comprehensive diagnostics and treatments for a broad patient base.

 

6. Which regions are key, and what are recent developments?

Asia-Pacific holds the largest share of the rise in liver cirrhosis/cancer; North America grows fastest. Key news: BD's FDA-cleared PeritX catheter (at-home drainage); Sequana's Alfapump approval; Pharmanovia's Korjuny launch (Dec 2025).